Sharing health management knowledge, product innovation insights, exploring the infinite possibilities of digital health together
9 articles, page 1/2
AMH (Anti-Mullerian Hormone) testing measures ovarian reserve and helps assess fertility potential. You can get tested at fertility clinics, OB/GYN offices, or direct-to-consumer lab services with CLIA-certified laboratory processing. Results typically arrive within 1-5 business days depending on the testing method. Costs range from $50 to $200 without insurance. When choosing a fertility clinic for AMH testing, look for SART membership, board-certified reproductive endocrinologists (REI), and CLIA-certified on-site or partnered laboratories. Telemedicine options now allow initial fertility consultations remotely, with lab orders sent to nearby draw stations for convenient AMH testing.
Anti-Mullerian Hormone (AMH) is widely known as a marker for IVF planning, but many women want to know what their AMH level means for natural conception. AMH reflects the size of your remaining ovarian follicle pool and correlates with how quickly you may conceive naturally, but it does not measure egg quality or guarantee any specific outcome. Women with low AMH can and do conceive naturally, particularly if they are young. Women with normal AMH may still face fertility challenges from other causes. This guide provides evidence-based data on natural conception rates by AMH level, explains why AMH predicts quantity over quality, and offers age-based guidelines for when to seek fertility evaluation based on your AMH result.
Anti-Mullerian Hormone (AMH) declines predictably as women age and is considered the most reliable biomarker for estimating when menopause will occur. Research shows that women with undetectable AMH levels are likely to reach menopause within 3-5 years, while AMH levels in the early reproductive years can predict menopause timing within a range of approximately 2-4 years. However, AMH-based menopause prediction is not a precise science. Individual variation, genetic factors, and health conditions all influence the actual age of menopause. This guide explains how AMH declines over time, the accuracy of menopause prediction using AMH, perimenopause AMH ranges, and how AMH compares to FSH for menopause timing estimation.
A low AMH result indicates diminished ovarian reserve (DOR) -- fewer remaining eggs than expected for your age. However, the ASRM Practice Committee (2020) emphasizes that DOR does not equal infertility, and studies show that women under 35 with low AMH retain reasonable natural conception rates. This guide covers DOR diagnosis criteria, evidence-based treatment options, IVF success rates stratified by AMH level, and emotional support resources.
Anti-Mullerian Hormone (AMH) is the most reliable blood biomarker for predicting ovarian response during IVF treatment. A single AMH blood test, drawn at any point in your menstrual cycle, helps your fertility specialist estimate how many eggs you are likely to produce during retrieval, select the appropriate medication dosage, and choose the optimal stimulation protocol. However, AMH predicts egg quantity, not egg quality or live birth rates. Women with low AMH can still achieve successful pregnancies, while women with high AMH may face risks of ovarian hyperstimulation syndrome. This guide covers AMH-based IVF protocol selection, expected egg retrieval numbers by AMH level, live birth rate data, and actionable steps for women with low AMH preparing for IVF.
Elevated AMH levels (above the 95th percentile for age) are found in approximately 70-80% of women with polycystic ovary syndrome and reflect the increased pool of small antral follicles characteristic of the condition. This guide covers the Rotterdam diagnostic criteria for PCOS, AMH's emerging role as a diagnostic biomarker, ovarian hyperstimulation syndrome (OHSS) risk stratification during IVF, and the metabolic implications of PCOS for long-term health.
